This is a Validated Antibody Database (VAD) review about human SPARC, based on 29 published articles (read how Labome selects the articles), using SPARC antibody in all methods. It is aimed to help Labome visitors find the most suited SPARC antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
SPARC synonym: BM-40; OI17; ON; ONT

Invitrogen
mouse monoclonal (ON1-1)
  • immunohistochemistry; dogs; fig 6
In order to elucidate the behavior of canine bone marrow stromal cells during differentiation into osteoblasts utilizing different implant biomaterials, Invitrogen SPARC antibody (Zymed, 33-5500) was used in immunohistochemistry on dogs samples (fig 6). Biotech Histochem (2016) ncbi
mouse monoclonal (ON1-1)
  • immunocytochemistry; human; fig 1
In order to characterize the growth and attachment of dental pulp stem cells on dentin with extra calcium, Invitrogen SPARC antibody (Zymed, 33-5500) was used in immunocytochemistry on human samples (fig 1). Arch Oral Biol (2016) ncbi
mouse monoclonal (ON1-1)
  • ELISA; human
In order to optimize a method to distinguish benign prostatic hypertrophy from prostate cancer, Invitrogen SPARC antibody (Invitrogen, 33-5500) was used in ELISA on human samples . PLoS ONE (2015) ncbi
mouse monoclonal (ON1-1)
  • immunohistochemistry; human; 1:400; fig 1
In order to evaluate carboplatin with nanoparticle albumin-bound-paclitaxel as first-line therapy for advanced non-small-cell lung cancer in a phase II trail, Invitrogen SPARC antibody (Invitrogen, 33-5500) was used in immunohistochemistry on human samples at 1:400 (fig 1). Clin Lung Cancer (2015) ncbi
mouse monoclonal (ON1-1)
  • immunohistochemistry; dogs; fig 5
In order to assess the use of cultured autologous bone marrow stromal cells on different scaffolds for healing defects in the tibias of dogs, Invitrogen SPARC antibody (Zymed, 33-5500) was used in immunohistochemistry on dogs samples (fig 5). Biotech Histochem (2015) ncbi
mouse monoclonal (ON1-1)
  • immunohistochemistry; human; 1:100
In order to evaluate the vasculogenic mimicry as a prognostic marker of human osteosarcoma, Invitrogen SPARC antibody (Invitrogen, 33-5500) was used in immunohistochemistry on human samples at 1:100. Hum Pathol (2014) ncbi
mouse monoclonal (ON1-1)
  • ELISA; human; fig 1
In order to test if the concentrations of SPARC are altered in patients with gestational diabetes mellitus, Invitrogen SPARC antibody (Life Technologies, ON1-1) was used in ELISA on human samples (fig 1). PLoS ONE (2013) ncbi
mouse monoclonal (ON1-1)
  • immunohistochemistry; human; 1:1000; fig 3
In order to test if the desmoid-type fibromatosis signature is specific to breast cancer or if it is found in multiple types of cancer, Invitrogen SPARC antibody (Invitrogen, 33-5500) was used in immunohistochemistry on human samples at 1:1000 (fig 3). Clin Cancer Res (2013) ncbi
mouse monoclonal (ON1-1)
  • immunohistochemistry - paraffin section; human; 10 ug/ml; fig 2
In order to examine the characteristics of the extracellular matrix and its impact on tumor progression, Invitrogen SPARC antibody (ZYMED, clone ON1-1) was used in immunohistochemistry - paraffin section on human samples at 10 ug/ml (fig 2). PLoS ONE (2013) ncbi
mouse monoclonal (ON1-1)
  • immunohistochemistry; rat; fig 5
In order to determine the effects of zoledronic acid on bone regeneration in response to expansion of the sagittal suture and relapse in rats, Invitrogen SPARC antibody (Zymed, 33-5500) was used in immunohistochemistry on rat samples (fig 5). Am J Orthod Dentofacial Orthop (2011) ncbi
mouse monoclonal (ON1-1)
  • immunohistochemistry - paraffin section; human; 1:6000; fig 1
In order to identify immunohistochemical markers to aid chondroid tumor diagnosis, Invitrogen SPARC antibody (Zymed, ON1-1) was used in immunohistochemistry - paraffin section on human samples at 1:6000 (fig 1). APMIS (2009) ncbi
mouse monoclonal (ON1-1)
  • immunohistochemistry; human
In order to investigate the molecular mechanism of bone remodeling with osteoclasts and osteoblasts, Invitrogen SPARC antibody (Zymed, ON1-1) was used in immunohistochemistry on human samples . Am J Pathol (2009) ncbi
mouse monoclonal (ON1-1)
  • immunohistochemistry - paraffin section; human; 1:500
In order to examine DNA methylation in intraductal papillary mucinous neoplasms, Invitrogen SPARC antibody (Zymed Laboratories, ON1-1) was used in immunohistochemistry - paraffin section on human samples at 1:500. Mod Pathol (2008) ncbi
mouse monoclonal (ON1-1)
  • immunocytochemistry; human; 5 ug/ml; fig 3
  • western blot; human; fig 2
In order to investigate how nonsteroidal anti-inflammatory drugs alter metastasis-related genes, Invitrogen SPARC antibody (Zymed, 33-5500) was used in immunocytochemistry on human samples at 5 ug/ml (fig 3) and in western blot on human samples (fig 2). Exp Biol Med (Maywood) (2008) ncbi
mouse monoclonal (ON1-1)
  • immunohistochemistry - paraffin section; human
In order to assess the prognostic significance of tumor and peritumoral secreted protein acidic and rich in cysteine expression in patients with pancreatic adenocarcinoma, Invitrogen SPARC antibody (Zymed, ON1-1) was used in immunohistochemistry - paraffin section on human samples . J Clin Oncol (2007) ncbi
mouse monoclonal (ON1-1)
  • immunohistochemistry; human; 1:200; fig 8B
  • western blot; human; 1:1000
In order to study the role of SPARC expression in impaired tumor growth, inhibited angiogenesis and extracellular matrix changes, Invitrogen SPARC antibody (Zymed, ON1-1) was used in immunohistochemistry on human samples at 1:200 (fig 8B) and in western blot on human samples at 1:1000. Int J Cancer (2006) ncbi
mouse monoclonal (ON1-1)
  • immunohistochemistry; human; fig 2
In order to report the expression pattern and methylation status of the SPARC gene in pancreatic cancer, Invitrogen SPARC antibody (Zymed, ON1-1) was used in immunohistochemistry on human samples (fig 2). Oncogene (2003) ncbi
Santa Cruz Biotechnology
mouse monoclonal (AON-5031)
  • immunohistochemistry; human; fig 3a
  • western blot; human; loading ...; fig 1c, 2a, 3b
Santa Cruz Biotechnology SPARC antibody (Santa Cruz Biotechnology, sc-73472) was used in immunohistochemistry on human samples (fig 3a) and in western blot on human samples (fig 1c, 2a, 3b). Theranostics (2021) ncbi
mouse monoclonal (AON-5031)
  • immunocytochemistry; human; loading ...; fig 2c
  • western blot; human; loading ...; fig 2a
Santa Cruz Biotechnology SPARC antibody (Santa Cruz, sc-73472) was used in immunocytochemistry on human samples (fig 2c) and in western blot on human samples (fig 2a). Int J Mol Sci (2020) ncbi
Abcam
domestic rabbit polyclonal
  • immunohistochemistry; mouse; loading ...
Abcam SPARC antibody (abcam, ab14174) was used in immunohistochemistry on mouse samples . Nat Commun (2021) ncbi
domestic rabbit polyclonal
  • western blot; rat; 1:500; loading ...; fig 2b
Abcam SPARC antibody (Abcam, ab55847) was used in western blot on rat samples at 1:500 (fig 2b). Biosci Rep (2019) ncbi
R&D Systems
domestic goat polyclonal
  • immunohistochemistry; mouse; loading ...
R&D Systems SPARC antibody (R&D, AF941) was used in immunohistochemistry on mouse samples . Nat Commun (2021) ncbi
Cell Signaling Technology
domestic rabbit monoclonal (D10F10)
  • western blot; human; loading ...; fig 3c
Cell Signaling Technology SPARC antibody (Cell Signaling, 8725) was used in western blot on human samples (fig 3c). Ther Adv Urol (2021) ncbi
domestic rabbit monoclonal (D10F10)
  • western blot; mouse; 1:1000; fig 5a
Cell Signaling Technology SPARC antibody (Cell Signaling, 8725) was used in western blot on mouse samples at 1:1000 (fig 5a). PLoS ONE (2021) ncbi
domestic rabbit polyclonal
  • western blot; human; loading ...; fig 1a
Cell Signaling Technology SPARC antibody (CST, 5420) was used in western blot on human samples (fig 1a). Cell Commun Signal (2019) ncbi
domestic rabbit monoclonal (D10F10)
  • western blot; human
Cell Signaling Technology SPARC antibody (Cell Signaling Technology, D10F10) was used in western blot on human samples . PLoS Pathog (2014) ncbi
Leica Biosystems
(15G12)
  • proximity ligation assay; human; 1:50; loading ...; fig 4
In order to investigate the interaction between SPARC and the actin cytoskeleton, Leica Biosystems SPARC antibody (Novocastra, ncl-o-nectin) was used in proximity ligation assay on human samples at 1:50 (fig 4). Am J Pathol (2017) ncbi
(15G12)
  • immunocytochemistry; human; fig 4c
Leica Biosystems SPARC antibody (Novocastra, 15G12) was used in immunocytochemistry on human samples (fig 4c). Folia Biol (Praha) (2016) ncbi
(15G12)
  • immunohistochemistry - paraffin section; human; 1:80; fig 1d
In order to study markers of the epithelial to mesenchymal transition using invasive lobular carcinoma samples, Leica Biosystems SPARC antibody (Novocastra, 15G12) was used in immunohistochemistry - paraffin section on human samples at 1:80 (fig 1d). J Pathol (2016) ncbi
Developmental Studies Hybridoma Bank
mouse monoclonal (AON-1)
  • immunocytochemistry; human; 1:5
Developmental Studies Hybridoma Bank SPARC antibody (DSHB, AON-1) was used in immunocytochemistry on human samples at 1:5. Anticancer Res (2004) ncbi
Articles Reviewed
  1. Kareddula A, Medina D, Petrosky W, Dolfi S, Tereshchenko I, Walton K, et al. The role of chromodomain helicase DNA binding protein 1 (CHD1) in promoting an invasive prostate cancer phenotype. Ther Adv Urol. 2021;13:17562872211022462 pubmed publisher
  2. Alcaraz L, Mallavialle A, David T, Derocq D, Delolme F, Dieryckx C, et al. A 9-kDa matricellular SPARC fragment released by cathepsin D exhibits pro-tumor activity in the triple-negative breast cancer microenvironment. Theranostics. 2021;11:6173-6192 pubmed publisher
  3. Tsutsui K, Machida H, Nakagawa A, Ahn K, Morita R, Sekiguchi K, et al. Mapping the molecular and structural specialization of the skin basement membrane for inter-tissue interactions. Nat Commun. 2021;12:2577 pubmed publisher
  4. Jones C, Sharick J, Colbert S, Shukla V, Zent J, Ostrowski M, et al. Pten regulates collagen fibrillogenesis by fibroblasts through SPARC. PLoS ONE. 2021;16:e0245653 pubmed publisher
  5. Nam B, Park H, Lee Y, Oh Y, Park J, Kim S, et al. TGFβ1 Suppressed Matrix Mineralization of Osteoblasts Differentiation by Regulating SMURF1-C/EBPβ-DKK1 Axis. Int J Mol Sci. 2020;21: pubmed publisher
  6. Wang Q, Yang Q, Zhang A, Kang Z, Wang Y, Zhang Z. Silencing of SPARC represses heterotopic ossification via inhibition of the MAPK signaling pathway. Biosci Rep. 2019;39: pubmed publisher
  7. Jiang S, Zhang M, Zhang Y, Zhou W, Zhu T, Ruan Q, et al. WNT5B governs the phenotype of basal-like breast cancer by activating WNT signaling. Cell Commun Signal. 2019;17:109 pubmed publisher
  8. Jørgensen L, Jepsen P, Boysen A, Dalgaard L, Hvid L, Ørtenblad N, et al. SPARC Interacts with Actin in Skeletal Muscle in Vitro and in Vivo. Am J Pathol. 2017;187:457-474 pubmed publisher
  9. Ozdal Kurt F, Tuglu I, Vatansever H, Tong S, Sen B, Deliloglu Gurhan S. The effect of different implant biomaterials on the behavior of canine bone marrow stromal cells during their differentiation into osteoblasts. Biotech Histochem. 2016;91:412-22 pubmed publisher
  10. Ozdal Kurt F, Sen B, Tuglu I, Vatansever S, Türk B, Deliloglu Gurhan I. Attachment and growth of dental pulp stem cells on dentin in presence of extra calcium. Arch Oral Biol. 2016;68:131-41 pubmed publisher
  11. Suchanek J, Suchánková Kleplová T, Rehacek V, Browne K, Soukup T. Proliferative Capacity and Phenotypical Alteration of Multipotent Ecto-Mesenchymal Stem Cells from Human Exfoliated Deciduous Teeth Cultured in Xenogeneic and Allogeneic Media. Folia Biol (Praha). 2016;62:1-14 pubmed
  12. McCart Reed A, Kutasovic J, Vargas A, Jayanthan J, Al Murrani A, Reid L, et al. An epithelial to mesenchymal transition programme does not usually drive the phenotype of invasive lobular carcinomas. J Pathol. 2016;238:489-94 pubmed publisher
  13. Jokerst J, Chen Z, Xu L, Nolley R, Chang E, Mitchell B, et al. A Magnetic Bead-Based Sensor for the Quantification of Multiple Prostate Cancer Biomarkers. PLoS ONE. 2015;10:e0139484 pubmed publisher
  14. Bertino E, Williams T, Nana Sinkam S, Shilo K, Chatterjee M, Mo X, et al. Stromal Caveolin-1 Is Associated With Response and Survival in a Phase II Trial of nab-Paclitaxel With Carboplatin for Advanced NSCLC Patients. Clin Lung Cancer. 2015;16:466-74 pubmed publisher
  15. Özdal Kurt F, Tuğlu I, Vatansever H, Tong S, Deliloğlu Gürhan S. The effect of autologous bone marrow stromal cells differentiated on scaffolds for canine tibial bone reconstruction. Biotech Histochem. 2015;90:516-28 pubmed publisher
  16. Ren K, Yao N, Wang G, Tian L, Ma J, Shi X, et al. Vasculogenic mimicry: a new prognostic sign of human osteosarcoma. Hum Pathol. 2014;45:2120-9 pubmed publisher
  17. Chattergoon M, Latanich R, Quinn J, Winter M, Buckheit R, Blankson J, et al. HIV and HCV activate the inflammasome in monocytes and macrophages via endosomal Toll-like receptors without induction of type 1 interferon. PLoS Pathog. 2014;10:e1004082 pubmed publisher
  18. Xu L, Ping F, Yin J, Xiao X, Xiang H, Ballantyne C, et al. Elevated plasma SPARC levels are associated with insulin resistance, dyslipidemia, and inflammation in gestational diabetes mellitus. PLoS ONE. 2013;8:e81615 pubmed publisher
  19. Chen J, Espinosa I, Lin A, Liao O, van de Rijn M, West R. Stromal responses among common carcinomas correlated with clinicopathologic features. Clin Cancer Res. 2013;19:5127-35 pubmed publisher
  20. Triulzi T, Casalini P, Sandri M, Ratti M, Carcangiu M, Colombo M, et al. Neoplastic and stromal cells contribute to an extracellular matrix gene expression profile defining a breast cancer subtype likely to progress. PLoS ONE. 2013;8:e56761 pubmed publisher
  21. Ozturk F, Babacan H, Inan S, Gumus C. Effects of bisphosphonates on sutural bone formation and relapse: A histologic and immunohistochemical study. Am J Orthod Dentofacial Orthop. 2011;140:e31-41 pubmed publisher
  22. Daugaard S, Christensen L, Høgdall E. Markers aiding the diagnosis of chondroid tumors: an immunohistochemical study including osteonectin, bcl-2, cox-2, actin, calponin, D2-40 (podoplanin), mdm-2, CD117 (c-kit), and YKL-40. APMIS. 2009;117:518-25 pubmed publisher
  23. Andersen T, Sondergaard T, Skorzynska K, Dagnaes Hansen F, Plesner T, Hauge E, et al. A physical mechanism for coupling bone resorption and formation in adult human bone. Am J Pathol. 2009;174:239-47 pubmed publisher
  24. Hong S, Kelly D, Griffith M, Omura N, Li A, Li C, et al. Multiple genes are hypermethylated in intraductal papillary mucinous neoplasms of the pancreas. Mod Pathol. 2008;21:1499-507 pubmed publisher
  25. Pan M, Chang H, Chuang L, Hung W. The nonsteroidal anti-inflammatory drug NS398 reactivates SPARC expression via promoter demethylation to attenuate invasiveness of lung cancer cells. Exp Biol Med (Maywood). 2008;233:456-62 pubmed publisher
  26. Infante J, Matsubayashi H, Sato N, Tonascia J, Klein A, Riall T, et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol. 2007;25:319-25 pubmed
  27. Chlenski A, Liu S, Guerrero L, Yang Q, Tian Y, Salwen H, et al. SPARC expression is associated with impaired tumor growth, inhibited angiogenesis and changes in the extracellular matrix. Int J Cancer. 2006;118:310-6 pubmed
  28. Pautke C, Schieker M, Tischer T, Kolk A, Neth P, Mutschler W, et al. Characterization of osteosarcoma cell lines MG-63, Saos-2 and U-2 OS in comparison to human osteoblasts. Anticancer Res. 2004;24:3743-8 pubmed
  29. Sato N, Fukushima N, Maehara N, Matsubayashi H, Koopmann J, Su G, et al. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene. 2003;22:5021-30 pubmed